All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-10-18T08:18:50.000Z

What are the future prospects for FLT3 mutated AML?

By Mark Maitland
Featured
Alexander Perl
Oct 18, 2021
Share:

Bookmark this article

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We Asked, What are the future prospects for FLT3 mutated acute myeloid leukemia (AML)?

What are the future prospects for FLT3 mutated AML?

Perl begins by outlining the standard of care for patients being treated intensely with newly diagnosed AML and upcoming studies investigating FLT3 inhibitors such as midostaurin, sorafenib, quizartinib, and gilteritinib. He goes on to discuss treatment prospects for patients ineligible for intensive chemo and post transplant maintenance. Finally, he highlights the importance of upcoming study MORPHO, which investigates gilteritinib as posttransplant maintenance.

More about...
AML-related mutationsSOHO 2021

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Related articles

Add bookmark

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new...

Sep 21, 2021
Add bookmark

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer...

Sep 21, 2021
Add bookmark

EHA 2019 | What effect does gilteritinib have on FLT3 mutated relapsed/refractory AML?

Alexander Perl presented the data from the ADMIRAL phase III trial of gilteritinib, a selective FLT3 inhibitor, for relapsed or refractory (R/R) acute myeloid...

Jun 17, 2019
Add bookmark

EHA 2019 | What effect does gilteritinib have on FLT3 mutated relapsed/refractory AML?

Alexander Perl presented the data from the ADMIRAL phase III trial of gilteritinib, a selective FLT3 inhibitor,...

Jun 17, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox